What Anavex did was develop a theory based on incredibly small numbers in subsets, hoping no misdiagnosis and that they can get their drug concentration high enough (certainly a significant issue) in a smaller number of people (limiting MMSE scores, removing patients with genetic issues with S1 receptors, focusing on particular APOE patient groups, etc).
What SAVA has done with a similar, yet larger non controlled group, is show they don't need to splice and dice data into subsets or hope patients can tolerate the drug to get to higher concentrations in order to potentially be effective. Anavex own peer reviewed data shows NOTHING LIKE the data seen here in MMSE patients scoring 16-28. There is no 2/3 showing improvement or nearly universal better than SOC. I'm not a fan of "precision medicine" when it comes to these subsets. I'll risk on the drug that has shown benefit without such data mining. That's just me though. They both could hit or miss.
Market Data 
Markets 
AI
